drugset
drugset / Trial / NCT05245539

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539 ↗

Phase 1 Completed 151 enrolled Cerevel Therapeutics, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.

Timeline

Start
2022-01-24
Primary completion
2022-10-19
Completion
2022-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule 10 mg Oral
Subject Emraclidine Small molecule 30 mg Oral

Indications

hypertensive disorder schizophrenia